A new study suggests an enzyme unique to Homo sapiens may have made us more competitive water seekers than our closest ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Geneoscopy, Inc ., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that Exact Sciences has withdrawn its motion for a ...

For leaders in business, failing to learn the lessons of a crisis can be disastrous. For leaders in government, when millions ...

"I am saddened and outraged that more citizens are not tuning into this war against scientific health research in the United ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

An announcement from Ionis Pharmaceuticals ( (IONS) ) is now available. On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved DAWNZERA™ (donidalorsen) for preventing hereditary ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.